ea0026p30 | Adrenal cortex | ECE2011
Mauclere-Denost S M D
, Tabarin A T
, Drui D D
, Chaillous L C
, Salenave S S
, Leboulleux S L
, Chabre O C
, Do-Cao C D C
, Dubourg H D
, Cuvelier M L C
, Young J Y
, Baudin E B
Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...